Batiraxcept

HOUSTON, July 28, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV, “the Company”), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the acceptance of two abstracts…

<!-- Name:DistributionId Value:8826496 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4500 -->…

Abstract selected for oral discussion on Genitourinary Cancer on Saturday, June 4, 2022Development of biomarker offers the potential of a first in class targeted therapy in renal cancerCompany has a registrational path for potential…